Introduction
Benign recurrent intrahepatic cholestasis (BRIC) is an autosomal-recessive cholestatic disorder [1] which was first described by Summerskill and Walshe in 1959 in two patients with recurring cholestasis [2, 3] . Ten years later, Tygstrup and Jensen [4] formulated the defining criteria as: (1) several episodes of pronounced jaundice with severe pruritus separated by symptom-free intervals lasting several months or years, (2) absence of a factor known to produce intrahepatic cholestasis (e.g. drug intake, pregnancy, intoxication), (3) biomechanical signs of obstructive jaundice but with normal intrahepatic and extrahepatic bile ducts (visualized by cholangiography), and finally (4) bile plugs within ducts in histological specimens [1, 2, 4, 5] .
Previously, Summerskill-Walshe-Tygstrup syndrome has been regarded as an idiopathic disease [1, 2] . Meanwhile it is known that BRIC displays a genetic heterogeneity and is associated with mutations in the ATP8B1 (BRIC 1) and ABCB11 (BRIC 2) genes and belongs to the 'canalicular transport defects' [1]. As it typically does not lead to liver cirrhosis, it is considered as a benign liver disease [5] . For the right diagnosis, both clinical and pathological features are pivotal [5, 6] . Therapeutically, in moderate cases, conservative treatment with cholestyramine, rifampicin [6] [7] [8] , steroids, phenobarbital, ursodeoxycholic acid or 5-adenosylmethionine [5] may be applied. In more severe cases, a nasobiliary drainage tube can be inserted, or surgical interventions such as partial biliary diversion or ileal bypass may be performed to relieve the patient's suffering [7] . Despite these various possibilities, in some patients symptoms -mostly pruritus -may still be resistant [5, 9] . For such severe cases, new therapeutic approaches are required to avoid liver transplantation as the ultimate required therapy. In 1988, several attempts succeeded in lowering bile acids by plasmapheresis [10, 11] . Additionally, since 2001, albumin dialysis (Molecular Adsorbent Recirculation System, MARS®) has been successfully applied to improve these patients' medical condition and to significantly reduce serum bilirubin and bile acid levels [8, 12, 13] .
In the case of our patient, the extracorporeal liver assist device Prometheus® (Fresenius Medical Care, Bad Homburg, Germany), which is frequently used in patients with severe cholestasis or liver failure as a bridging procedure to transplantation [14, 15] , has been applied to resolve therapy-resistant pruritus.
Case Report
We report a 45-year-old Caucasian woman with Summerskill-Walshe-Tygstrup syndrome which was first diagnosed in 1998. Despite extensive conservative therapy with prednisolone (5-10 mg/day), ursodeoxycholic acid (3 × 500 mg/day) and cholestyramine (3 × 4 g/day), she suffered from intermittent attacks of cholestatic jaundice, severe pruritus and anxious nervousness. On clinical examination, she had never had any evidence of hepatomegaly, ascites or encephalopathy. Usually, serum bile acids were elevated at 22.5 ± 2.7 µmol/l (normal <6 µmol/l), while transaminases as well as γ-glutamyltransferase (γ-GT) and alkaline phosphatase (AP) remained at approximately normal values (<35 U/l), respectively. Virology (hepatitis A-E, CMV, EBV and HSV) and immunological serology (ANA, AMA, ANCA, SMA, SLA, LKM, γ-globulin and IgG/IgM) were all negative. The patient denied any alcohol or drug abuse. No liver diseases were known in the family history. However, both the patient's grandmother and mother suffered from cholecystolithiasis.
In March 2008 the patient presented with profound pruritus and agitation. Bile acids were highly elevated at 35.3 µmol/l (normal <6 µmol/l). Ultrasound examination revealed normal liver morphology without signs of obstructive cholestasis (diameter of the common bile duct 3 mm). Additionally, a liver biopsy was performed which demonstrated normal hepatocyte architecture without inflammatory cells or bile plugs within the canaliculi ( fig. 1) . Following endoscopic retrograde cholangiopancreatography, a 7 Fr nasobiliary drainage tube was inserted ( fig. 2) , unfortunately without sustained clinical benefit. Therefore, indication for Prometheus® liver dialysis was stated. The first 3 dialysis cycles were performed in April 2008, followed by another 5 cycles in June 2008, leading to complete recovery and decreasing laboratory parameters. In the following years, Prometheus® liver dialysis was performed in regular intervals as demonstrated in fig. 3 . After these sessions, bile acids were lowered significantly by 78% from an average of 22.5 ± 2.7 to 7.3 ± 1.7 µmol/l (p = 0.003). Due to cicatrization of the dialysis catheter, a Cimino-Brescia fistula was finally applied in January 2011.
Discussion
We here report a patient with characteristic features of BRIC, occurring frequently with insistent symptoms. She suffered from intermitting severe pruritus as well as infrequent jaundice. This disease is remarkable for its discrepancy between a rise in serum bile acids at the onset of each attack and a later rise in total serum bilirubin levels. Due to conservative treatment with prednisolone (5-10 mg/day), ursodeoxycholic acid (3 × 500 mg/day) and cholestyramine (3 × 4 g/day), the icteric episodes could be reduced and only appeared rarely. In contrast, conservative treatment did not have any positive effects on agonizing pruritus. During this stage, laboratory parameters revealed the typical periodic elevation of total serum bilirubin and bile acids. However, transaminases, AP and γ-GT were less affected (<35 U/l). Whenever intractable pruritus appeared, liver dialysis using the Prometheus® system was performed. The first cycle was set after worsening of the patient's condition when a 7 Fr nasobiliary drainage tube dislocated in March 2008. In the following years, 3 up to 5 cycles of liver dialysis per session were necessary to normalize laboratory parameters and relieve the patient's suffering.
This range for dialysis sessions is in accordance with other studies describing the application of Prometheus® in patients with insistent pruritus [16] [17] [18] . The pathogenesis of cholestatic pruritus is not completely clear. Besides bile acids, which apparently seem to play a major role as pruritogens, elevated levels of endogenous opioids and amphiphilic lysophosphatidic acid (LPA) were also found in patients with cholestatic pruritus [16] . In contrast to bile acids, LPA and autotaxin (the enzyme responsible for the transformation of lysophosphatidylcholine into LPA) plasma levels were demonstrated to correlate significantly with the severity of patients' pruritus [19] . This indicates a crucial role of LPA and autotaxin in the pathophysiology of pruritus.
Conservative treatment is based upon this knowledge as e.g. the bile acid sequestrate cholestyramine is recommended as the first-line treatment by EASL and AASLD [17] . Involvement of the opioid system furthermore allows the application of opioid antagonists [5] such as naltrexone to resolve pruritus. Reported positive effects of the serotonin re-uptake inhibitor sertraline actually indicate an involvement of the serotonin system [16] . Despite these numerous mechanisms by which the pathogenesis of pruritus can already be affected therapeutically to relieve the majority of patients from pruritus, some of them remain resistant to these therapies. As severe pruritus may lead to reduced quality of life and even to suicide [16, 17] , the necessity for an effective therapy becomes obvious. In these patients, e.g. with primary biliary cirrhosis [20] , liver transplantation may become the ultimate therapeutic option [17] .
Until now, several studies have provided evidence for extracorporeal liver support systems, first for MARS® and later for Prometheus®, to be an effective and safe therapeutic alternative for patients with cholestatic pruritus [8, 12, 13, 16, 17] . With regard to the elimination of albumin-bound molecules such as bilirubin (strongly albumin-bound) or bile acids (less tightly albumin-bound), there are slight differences between these two methods [18] . Krisper and Stauber [18] characterized the dialysis performance of Prometheus® as less selective to albumin-bound molecules and more efficient at the same time as compared to MARS®. Concerning bile acid removal, Stadlbauer et al. [21] found similar efficiency for both Prometheus® and MARS®, while a change in the particular bile acid profile towards hydrophobic bile acids was observed only under Prometheus® treatment. Besides changes in white blood cell count, no adverse effects have been reported so far [18, 22] . Furthermore, Leckie et al. [17] described decreasing hemoglobin and thrombocyte levels, however not requiring further treatment.
Conclusion
Because of its rareness Summerskill-Walshe-Tygstrup syndrome is first considered in the differential diagnosis of cholestasis after many years of extensive investigations. Treatment is difficult, purely symptomatic, and unfortunately often without marked effects. However, in some cases, Prometheus® liver dialysis appears to be a beneficial alternative for patients with BRIC-related symptoms -mainly intractable pruritusresistant to conservative treatment.
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